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Abstract
Brain-derived neurotrophic factor (BDNF) has been pro-
posed as a biomarker of schizophrenia and, more spe-
cifically, as a biomarker of cognitive recovery. Evidence 
collected in this review indicates that BDNF is relevant 
in the pathophysiology of schizophrenia and could play 
a role as a marker of clinical response. BDNF has been 
shown to play a positive role as a marker in antipsy-
chotic treatment, and it has been demonstrated that 
typical antipsychotics decrease BDNF levels while atyp-
ical antipsychotics maintain or increase serum BDNF 
levels. Furthermore, BDNF levels have been associated 
with severe cognitive impairments in patients with 
schizophrenia. Consequently, BDNF has been proposed 
as a candidate target of strategies to aid the cognitive 
recovery process. There is some evidence suggesting 
that BDNF could be mediating neurobiological process-
es underlying cognitive recovery. Thus, serum BDNF 
levels seem to be involved in some synaptic plasticity 
and neurotransmission processes. Additionally, serum 
BDNF levels significantly increased in schizophrenia 
subjects after neuroplasticity-based cognitive training. 
If positive replications of those findings are published 
in the future then serum BDNF levels could be definite-
ly postulated as a peripheral biomarker for the effects 
of intensive cognitive training or any sort of cognitive 
recovery in schizophrenia. All in all, the current consid-
eration of BDNF as a biomarker of cognitive recovery 
in schizophrenia is promising but still premature.
© 2013 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: The lack of diagnostic and treatment mark-
ers is one of the most important problems in clinical 
practice. Brain-derived neurotrophic factor (BDNF) has 
been proposed as a biomarker of schizophrenia and, 
more specifically, as a biomarker of cognitive recov-
ery. Evidence collected in this review indicates that 
there is evidence suggesting that serum BDNF levels 
are involved in some synaptic plasticity processes. Ad-
ditionally, serum BDNF levels significantly increased in 
schizophrenia subjects after neuroplasticity-based cog-
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nitive training. All in all, the current consideration of 
BDNF as a biomarker of cognitive recovery in schizo-
phrenia is promising but still premature.
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INTRODUCTION
The lack of  diagnostic and treatment markers is one 
of  the most important problems in clinical practice. 
Researchers are deeply involved in the identification of  
validated markers, particularly biomarkers that could 
be useful in predicting treatment responses to different 
therapeutics. One of  the most important challenges of  
schizophrenia research is to establish biological mark-
ers that can predict clinical outcome and identify clinical 
stages in these patients. Molecular genetics, analysis of  
serum and cerebrospinal fluid (CSF), and structural and 
functional neuroimaging have provided an attractive field 
of  research for biomarkers[1]. For many reasons, such as 
small effect sizes and individual rarity, gene studies have 
traditionally shown that genetic markers are not suitable 
as diagnostic markers[2]. In this line, the study of  CSF pa-
rameters has yielded a number of  interesting candidate 
biomarkers, but this research has only recent begun[3]. 
In contrast, despite particularly promising research on 
neuroimaging, available techniques for evaluating struc-
tural and functional brain changes make them unsuitable 
as biomarkers in schizophrenia[4]. Further biomarker 
research is needed in schizophrenia. However, evidence 
suggests both that BDNF is relevant in the pathophysi-
ology of  schizophrenia and that BDNF is potentially 
more useful as a biomarker for diagnostic and prognos-
tic purposes than are other potential biomarkers[5].
A biomarker has been defined by the United States 
Food and Drug Administration (FDA) as “A charac-
teristic that is objectively measured and evaluated as an 
indicator of  normal biological processes, pathogenic 
processes, or pharmacological responses to a therapeutic 
intervention”. Biomarkers have been suggested to have 
the potential to augment the chances of  successful drug 
and therapeutic development through better target vali-
dation, provision of  surrogate end-points and patient 
stratification[6]. Recently, cognitive recovery has been 
considered among the most important targets in the 
treatment of  patients with schizophrenia. Consequently, 
the identification of  biomarkers of  cognitive recovery is 
relevant not only for diagnostic purposes but also for the 
development of  new approaches to treat cognitive im-
pairment in schizophrenia[7]. Brain-derived neurotrophic 
factor (BDNF) has been proposed as one of  the stron-
ger biomarker candidates in schizophrenia and, more 
specifically, as a biomarker of  cognitive recovery[5]. 
BRAIN-DERIVED NEUROTROPHIC FAC-
TOR
Neurotrophins are growth factors that play an impor-
tant role in the survival, development, and functional-
ism of  neurons. They prevent neurons from triggering 
programmed cell-death, which prolongs their survival. 
They are also involved in the formation of  new neurons 
in certain areas of  the brain. BDNF is one of  the most 
studied neurotrophins. The properties of  BDNF vary 
according to the brain region studied. BDNF has been 
described as a modulator of  neuronal survival and differ-
entiation, synaptic plasticity, and higher order cognitive 
functions such as learning and memory[8-10]. Moreover, 
there is also evidence that indicates a role for BDNF in 
the development of  the cardiovascular system[11,12] and 
in the growth, survival, and chemoresistance of  tumour 
cells in various types of  cancer, including Hodgkin lym-
phoma, myeloma, and neuroblastoma[13-17]. 
BDNF is mainly synthesised in the brain and spinal 
cord by glial cells[18], but is also produced by Schwann 
cells associated with peripheral motor neurons[19]. BDNF 
is synthesised as a precursor (proBDNF) that is cleaved 
afterwards to generate the mature protein. Although it 
was believed that proBDNF had no function, work by 
Hempstead and collaborators reported that, by interact-
ing with the p75 neurotrophin receptor, proBDNF could 
induce the opposite effect to that of  mature BDNF, 
leading to cell death[20]. This work has opened a new 
line in the study of  the mechanisms underlying BDNF 
because mature BDNF mainly acts through a different 
receptor, the tyrosine kinase receptor B (TrkB)[20]. In ad-
dition, it is known that BDNF can pass the blood-brain 
barrier, reaching non-neuronal tissues, such as the heart, 
lungs and platelets[21-24]. However, little is known about 
the function of  non-neuronal BDNF. Moreover, BDNF 
mRNA has been found in several peripheral locations, 
such as activated human T cells, B cells, monocytes[25], 
the heart[26], the retina, smooth muscle[12], the lungs[27-28], 
endothelial cells[29] and platelets[24,29].
Given the difficulty of  studying BDNF in situ in the 
brain, there has been growing interest in the accurate as-
sessment of  BDNF activity in the periphery. Studies in 
murine models have shown a good correlation between 
BDNF levels in the brain and circulating levels of  the 
protein[30]. The amount of  BDNF in serum, plasma and 
whole blood samples is commonly determined by using 
ELISA techniques with relatively high specificity and 
sensitivity. In spite of  all the different sources of  BDNF, 
it is believed that BDNF released from platelets is the 
major contributor to serum samples. BDNF stored in 
platelets is most likely derived from both the circulating 
plasma pool and from resident cells in the brain[30] and 
other organs[22,29,31,32]. 
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Measured BDNF levels are highly dependent on the 
methodology used[33]. Karege et al[34] demonstrated that 
the stability of  BDNF assessed in whole blood, serum, 
and plasma samples varied among different laboratories. 
Nonetheless, the accuracy and reproducibility of  BDNF 
determination in serum has been validated[35]. However, 
there is still little consensus regarding standardised pro-
tocols for plasma collection and BDNF dosage. Interest-
ingly, there have been reported changes in serum and 
blood BDNF levels in patients with neuropsychiatric 
disorders such as depression[21,36], schizophrenia[37], Al-
zheimer’s disease[38], multiple sclerosis[39], and anorexia[40] 
when compared to healthy individuals. 
GENETIC POLYMORPHISM OF BDNF
The BDNF gene (chromosome 11p13-14) encodes a 
precursor peptide (proBDNF) that is proteolytically 
cleaved to form the mature BDNF protein. This gene 
contains a functional polymorphism that has been wide-
ly studied in genetic association and gene-environment 
studies in psychiatry research[41,42]. This single nucleotide 
polymorphism (SNP) consists of  a guanine substitution 
for an adenine in the position 196 of  the gene (rs6265), 
provoking a change of  a Valine (Val) to a Methionine 
(Met) in amino acid 66 of  the protein. As a functional 
polymorphism, it has been claimed that the Val variant is 
associated with higher neuronal BDNF secretory activ-
ity than is the Met allele. Additionally, the co-expression 
of  Val and Met alleles in heterozygotes results in less ef-
ficient intracellular trafficking and processing, leading to 
decreased BDNF secretion[43,44].
Genetic studies have revealed that the association 
between BDNF and schizophrenia has not been defini-
tively established. The single nucleotide polymorphisms 
C270T (in the 5’ non-coding region) and Val66Met are 
two common functional genetic polymorphisms of  the 
BDNF gene. A meta-analysis of  case-control studies[42] 
stressed the association of  this polymorphism with the 
risk of  schizophrenia and other mental disorders, such 
as substance-related disorders and eating disorders. This 
study also showed that individuals with the Met/Met 
homozygous allele had 19% higher risk of  developing 
schizophrenia and other psychotic disorders than did 
those with the Val/Met heterozygous alleles. However, 
another meta-analytic study of  two of  the most exten-
sively studied BDNF polymorphisms, Val66Met and 
C270T, did not find an association of  the Val66Met 
polymorphism with schizophrenia[45]. Nonetheless, sev-
eral studies have shown positive associations between 
the BDNF Val66Met genetic variant and several aspects 
of  the phenomenology of  schizophrenia, such as age of  
onset, clinical symptoms, aggressive behaviour, suicide 
attempt, brain morphology, and cognitive function[41]. 
BDNF LEVELS AND SCHIZOPHRENIA
Schizophrenia has been conceptualised as being es-
sentially a neurodevelopmental disorder[46,47]. It is well 
known that BDNF plays a key role in a number of  
processes that are thought to be impaired in schizophre-
nia, ranging from neuronal differentiation to neurite 
outgrowth and neuronal survival[48]. In addition, BDNF 
seems to be crucial to synaptic transmission and vari-
ous cognitive processes that are severely impaired in 
schizophrenia. Currently, a considerable amount of  data 
are available that highlight the role of  BDNF in the 
pathophysiology of  schizophrenia[49] in both chronic pa-
tients and first episodes. Commonly, it has been assumed 
that determination of  BDNF levels in peripheral se-
rum might be a useful measure. On one hand, levels of  
BDNF in peripheral serum seem to be correlated with 
BDNF concentrations in the central nervous system[30]. 
On the other hand, BDNF is able to cross the blood-
brain barrier[32]. Unfortunately, the studies that measure 
serum BDNF concentrations in patients with schizo-
phrenia are not conclusive and have even produced 
some conflicting results. 
The majority of  relevant studies report lower serum 
BDNF levels in schizophrenia patients compared to 
healthy controls[37,50-54]. However, other studies could 
not find any differences between schizophrenia patients 
and healthy controls[55,56]. Further, some studies have 
even found higher serum BDNF levels in patients with 
schizophrenia[57,58]. To clarify these controversial results, 
Green et al[59] assessed the published data in a meta-anal-
ysis. After a rigorous selection of  the works with bet-
ter methodology, the authors were able to demonstrate 
reduced serum BDNF levels in schizophrenia patients, 
not only for medicated patients but also for drug-naïve 
patients; no differences were shown between males and 
females. In addition, using meta-regression techniques 
Green et al[59] showed a significant association between 
reduced BDNF and increased age, but no association 
was found for medication dosage. In conclusion, after 
controlling for heterogeneity of  samples and method-
ological aspects, these authors suggested that blood 
levels of  BDNF are actually reduced in medicated and 
drug-naive patients with schizophrenia.
Although many studies about BDNF levels have been 
conducted in chronic schizophrenia patients, a few recent 
studies have examined BDNF profiles in first-episode 
patients. The earliest study to be conducted with first 
episodes and drug-naïve patients reported a significant de-
crease in plasma BDNF levels compared with controls[60]. 
The authors found a significant association between 
plasma BDNF levels and positive and negative syndrome 
scale scores. Since this study, a number of  studies have 
replicated those findings suggesting differences in BDNF 
levels in first-episode patients. Jindal et al[61] showed a sig-
nificant decrease in serum BDNF levels in patients with 
first episode schizophrenic psychosis but not in patients 
with non-schizophrenic psychosis. Unfortunately, they 
could not find significant correlations between BDNF 
levels and the severity of  positive and negative symp-
toms or overall functioning. A different study tested 
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the presence of  cerebrospinal fluid (CSF) BDNF levels 
in drug-naïve first-episode patients[62]. Compared with 
controls, a significant decrease in CSF BDNF levels was 
found and they were significantly related with plasma 
levels. In addition, CSF and plasma BDNF levels also 
showed a significant negative correlation with baseline 
positive symptoms. Finally, a study conducted by the 
research team of  Rizos[63] tried to determine the asso-
ciation between serum BDNF levels and hippocampal 
volumes in a sample of  first psychotic episode drug-
naïve schizophrenia patients. The authors found serum 
BDNF levels significantly reduced in the sample of  first-
episode patients when compared to levels of  healthy 
subjects. Consequently, hippocampal volume was already 
decreased at the onset of  schizophrenia in first-episode 
patients. Interestingly, BDNF levels and hippocam-
pal volume reduction were significantly related, which 
suggests a putative relationship between lower serum 
BDNF levels and a reduction of  hippocampal volume.
BDNF AND NEUROTRANSMITTERS 
BDNF plays an important role as a regulator of  syn-
aptic transmission and has been associated with the 
pathophysiology of  schizophrenia[64]. Furthermore, its 
relationship with dysfunctions in the dopaminergic, glu-
tamatergic, and serotonergic neurotransmitter systems 
has been widely studied.
BDNF is a neurotrophic protein that is synthesised by 
dopamine cells and has been closely linked to the func-
tion of  the dopaminergic system. It has been shown 
to be expressed throughout the cerebral cortex, hip-
pocampus, basal forebrain, striatum, hypothalamus, 
and cerebellum neurons[65]. With regards to synaptic 
transmission, BDNF has also been shown to control 
the expression of  D2-like receptors, Dopamine 1 and 
Dopamine 3 (D1, D3), in adults through the control of  
specific dopamine genes[66-68]. For this reason, BDNF is 
an important modulator of  the dopaminergic system, 
and its changes can be observed in the brain and in the 
plasma of  patients with schizophrenia[66].
Exposure to BDNF or a lack of  this neurotrophin 
results in alterations to both excitatory and inhibitory 
synaptic systems[64]. The role of  BDNF in the glutama-
tergic system has been well studied (Figure 1). BDNF 
promotes the development of  GABA neurons and the 
expression of  GABA-related proteins, such as GAD67 
and GAT, in the cortex and other brain regions[65]. In 
rodents, BDNF regulates the GABAergic system in the 
hippocampus. In subjects with schizophrenia, altered 
GABA neurotransmission may contribute to prefrontal 
cortex dysfunction[69].
Some evidence suggests that BDNF has an influ-
ence on the development of  the serotonergic system 
by promoting the survival and differentiation of  5-hy-
droxytryptamine (5-HT) neurons both in vivo and in 
vitro[70,71]. Furthermore, BDNF stimulates the expression 
of  S100 beta in astrocytes and the production of  myelin 
basic protein oligodendrocytes[70]. In mice, alterations in 
BDNF expression result in physiological disturbances in 
5-HT neurons that have been shown to be deteriorated 
in advanced age[70]. In humans, high levels of  central se-
rotonergic activity are associated with high BDNF serum 
concentrations[72].
BDNF AND SYNAPTIC PLASTICITY 
Although the aetiology of  schizophrenia is still un-
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Figure 1  Role of brain-derived neurotrophic factor in synaptic transmission. BDNF: Brain-derived neurotrophic factor.
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known, neuroimaging studies have consistently dem-
onstrated brain abnormalities in patients with schizo-
phrenia. These studies revealed significant reductions in 
gray matter volume in the cortex and hippocampus and 
decreases in neurons of  the dorsal thalamus[73]. Within 
first-episode psychosis patients, a systematic review and 
meta-analysis has shown volumetric deficits in the hip-
pocampus and in cortical grey matter, specifically in tem-
poral grey matter[73]. Furthermore, histological studies 
have shown a significant reduction in synaptic and den-
dritic markers in the brains of  schizophrenia patients[74]. 
Recent evidence suggests that BDNF has an impor-
tant role in the growth and development of  the central 
and peripheral nervous system and is associated with dis-
ruptions in the brain structure of  patients with schizo-
phrenia[75]. In previous studies, BDNF has been reported 
to regulate axonal and dendritic development and the 
differentiation and survival of  new neurons by increas-
ing the number and length of  axons and their branch-
es[64,70]. In mice, BDNF has demonstrated a specific role 
by promoting survival of  embryonic retina ganglion cells 
and mesencephalic dopaminergic neurons in vitro. After 
administration of  high BDNF concentrations in rodents, 
an extensive neuronal growth was observed[76].
BDNF AND COGNITION 
BDNF has been shown to mediate some processes of  
cognition. It has demonstrated its role as a regulator of  
axonal and dendritic branching[77,78]. Thus, the process of  
hippocampal long-term potentiation implies a process 
of  synaptic strengthening associated with learning and 
memory through its functional TrkB receptor[79,80]. In 
relation to schizophrenia, a study detected a significant 
positive correlation between serum BDNF levels and 
decreased cognitive functioning in 250 Chinese inpa-
tients with schizophrenia[81]. In another study, serum 
truncated-BDNF abundance predicted a high presence 
of  cognitive impairments, showing 67.5% of  sensitivity 
and 97.5% of  specificity[82] in the prediction. This result 
suggests that deficiency in pro-BDNF processing may 
be involved in the mechanism underlying the cognitive 
impairments observed in schizophrenia. In addition, 
impairment in spatial learning and memory has been 
found in BDNF-knockout mice[83]. Conversely, single 
intrahippocampal BDNF administration seems to af-
fect the behavioural flexibility of  rats in a Morris water-
maze task[84]. Studies have also found impairments in 
long-term potentiation in BDNF gene-deleted mice[85]. 
These data support the role of  BDNF in cognitive im-
pairments observed in schizophrenia and suggest that 
BDNF could be a potential marker of  cognition, as it is 
involved in learning and memory processes[5]. 
BDNF AS A POTENTIAL BIOMARKER 
Currently, pharmacological response is mainly a process 
determined by a trial and error strategy. Identification of  
biomarkers in the near future could allow us to identify 
patients who are more likely to respond to a particular 
treatment and even determine their sensitivity to side ef-
fects. However, not only would this allow us to stratify 
patients according to their likely treatment response but 
it could also help clinicians and patients to partially avoid 
the uncertainty of  the trial and error process. BDNF has 
been strongly proposed as a biomarker in schizophre-
nia and more specifically as a biomarker of  cognitive 
recovery. But, is there now enough evidence to consider 
DBNF as a biomarker? As previously mentioned, a bio-
marker needs to have three core characteristics: (1) To 
be an indicator of  normal biological processes; (2) To 
be an indicator of  pathogenic processes; and (3) To be a 
marker of  response to therapeutic interventions.
Indicator of normal biological processes
BDNF seems to play a crucial role in normal cogni-
tive functions such as learning and memory. Its role 
as a regulator of  axonal and dendritic branching has 
been shown in various studies[77,78]. Thus, the process 
of  hippocampal long-term potentiation, which implies 
a process of  synaptic strengthening associated with 
learning and memory through its functional TrkB recep-
tor has also been found[79]. In addition to this, BDNF 
signalling has been implicated in the regulation of  adult 
neurogenesis, suggesting its prominent role in synaptic 
plasticity and cognition[86]. On the other hand, the genet-
ics of  BDNF show that polymorphisms are relevant to 
understanding normal neurotrophic processes. Variation 
of  BDNF polymorphisms includes a single-nucleotide 
polymorphism (SNP), rs6265, in the conserved, 5′-pro-
protein-coding region; this entails a valine-to-methionine 
substitution (Val66Met). This last polymorphism has 
been suggested to cause inefficient BDNF trafficking 
and a reduced activity-dependent BDNF secretion. 
Indicator of pathogenic processes
Some studies have suggested that BDNF is strongly 
implicated in the pathophysiology of  schizophrenia in 
both first-episode patients and chronic schizophrenia 
patients. Within first-episode schizophrenia patients, a 
number of  studies have shown a significant decrease in 
plasma BDNF levels[87]. In addition, serum BDNF levels 
are lower in chronic schizophrenia patients compared 
to healthy controls[51]. In relation to reduced brain vol-
umes in first-episode and chronic schizophrenia patients, 
recent studies have found a correlation to lower serum 
BDNF levels[63], specifically in reduced hippocampal 
volume[88]. BDNF levels in serum or CSF have been as-
sociated with the presence of  schizophrenia in general 
and to other impairments in cognition. BDNF polymor-
phism is involved in less efficient intracellular trafficking 
and processing. This leads to decreased BDNF secretion 
and possibly to disturbances in neurotransmission pro-
cesses, which may contribute to prefrontal cortex dys-
function. Neuroimaging studies have shown that reduced 
brain volumes in first-episode and chronic schizophrenia 
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patients are related to lower serum BDNF levels[63] and, 
specifically, to reduced hippocampal volume[88]. Finally, 
using functional neuroimaging, Eisenberg and collabora-
tors[89] have suggested that Val66Met polymorphism is 
significantly associated with hippocampal dysfunction.
Marker of response to therapeutic interventions 
Studies that aim to measure the effects of  antipsychot-
ics on BDNF have produced varying results depending 
on the type of  antipsychotic used in the study[64]. Thus, 
some studies suggested that typical antipsychotics seem 
to reduce BDNF expression while atypical antipsychot-
ics could increase BDNF expression, but these studies 
were carried out as animal experiments. Unfortunately, 
studies with clinical samples in humans are still scarce[90]. 
In the particular case of  treatments that target cogni-
tion, studies are even scarcer. Nonetheless, BDNF has 
been shown to mediate some processes of  cognitive 
change. There is some evidence about BDNF’s role as 
a regulator of  axonal and dendritic branching[77,78]. The 
process of  hippocampal long-term potentiation, which 
implies a process of  synaptic strengthening, has been 
associated with learning and memory through its func-
tional TrkB receptor[79,80]. Furthermore, a recent study 
conducted by Vinogradov et al[91] has directly tested 
whether neuroplasticity-based cognitive training is able 
to modify serum BDNF levels in schizophrenia patients. 
Samples consisted of  56 schizophrenia outpatients and 
16 matched healthy comparison subjects. Both groups 
were assessed on baseline cognitive performance and 
serum BDNF levels. Schizophrenia subjects were ran-
domly assigned to either 50 h of  computerised auditory 
training or a computer-game control condition; this 
was followed by reassessment of  cognition and serum 
BDNF levels. At baseline, schizophrenia participants 
had significantly lower serum BDNF levels than did 
healthy controls. Subjects who engaged in computerised 
cognitive training designed to improve auditory process-
ing showed significant cognitive gains and a significant 
increase in serum BDNF when compared with subjects 
who played computer games (control condition). In 
sum, in a repeated-measures analyses of  variance ap-
proach, subjects following cognitive training showed 
a statistically significant gain in global cognition (ap-
proximately 0.36 SD) from baseline to endpoint; sub-
jects in the control group showed no change in global 
cognition (0.01 SD). After 10 wk, subjects following 
the neurocognitive training were able to increase their 
mean serum BDNF levels (mean ± SD, 25.27 ± 10.34) 
to the same level as healthy controls (mean ± SD, 31.30 
± 8.95); the control group showed no change. After the 
treatment, authors calculated the standardised mean dif-
ference (Cohen’s d) in BDNF levels between the control 
group and the therapeutic group and found a medium 
effect size of  0.67. Although this study has not been 
replicated, it opens a pathway in clinical research. It is 
probable that serum BDNF levels would be significantly 
increased after neuroplasticity-based cognitive training 
in schizophrenia subjects. If  positive replications are 
published, then serum BDNF levels could be postulated 
as a peripheral biomarker for the effects of  intensive 
cognitive training or any sort of  cognitive recovery in 
schizophrenia. 
Furthermore, pharmacogenetic studies have shown 
that the BDNF Val66 Met polymorphism could be 
helpful as an outcome predictor not only for cognitive 
recovery but also for drug response and adverse side ef-
fects. It has been suggested that BDNF polymorphism 
may be associated with antipsychotic therapeutic ef-
fects[41,92,93], treatment resistance[94] and adverse effects 
including weigh gain[95], tardive dyskinesis[96] and extra-
pyramidal syndrome[97]. Interestingly, Zhang et al[96] have 
indicated that BDNF genetic variants could be associ-
ated with antipsychotic treatment resistance. 
CONCLUSION
Evidence collected in this review indicates that BDNF 
is relevant in the pathophysiology of  schizophrenia and 
could play a role as a marker of  clinical response. It has 
been confirmed that BDNF plays a crucial role as a reg-
ulator of  synaptic transmission and seems to be related 
to dysfunctions in principal neurotransmitter systems, 
such as the dopaminergic, glutamatergic and serotonergic 
neurotransmitter systems. Particularly, BDNF has been 
associated with disruptions in brain structure and neu-
rodevelopmental processes. Some studies suggest that 
BDNF levels are altered in schizophrenia patients. Con-
sequently, the relationship between psychotic symptoms 
and alterations in the expression of  BDNF has been 
well established. More specifically, BDNF might be play-
ing a role as a marker of  antipsychotic treatment because 
studies show that typical antipsychotics seem to decrease 
BDNF levels while atypical antipsychotics maintain or 
increase serum BDNF levels. 
Regarding cognitive recovery, the evidence gathered in 
this review confirms the role of  BDNF in brain plasticity 
and cognition. There is some evidence suggesting the role 
of  BDNF as a regulator of  axonal and dendritic branch-
ing. BDNF might also be involved in the process of  hip-
pocampal long-term potentiation through the process of  
synaptic strengthening. In patients with schizophrenia, 
BDNF levels have been related to more severe impair-
ment in cognition. Consequently, BDNF might be pro-
posed as a biomarker of  the cognitive recovery process. It 
has been suggested that BDNF mediates some processes 
of  cognitive change. Thus, serum BDNF levels seem 
to be significantly increased after neuroplasticity-based 
cognitive training in schizophrenia subjects. If  positive 
replications are published then serum BDNF levels could 
be postulated as a peripheral biomarker for the effects of  
intensive cognitive training or any sort of  cognitive recov-
ery in schizophrenia. 
Unfortunately, the effect of  neuromodulation on 
BDNF is still far from being completely understood. 
Moreover, the specificity of  BDNF as a biomarker for 
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schizophrenia cannot be stated because reduction in 
BDNF has also been observed in patients with neuro-
degenerative disorders and other neuropsychiatric ill-
nesses. Consequently, more studies are needed in order 
to establish BDNF as a marker of  cognitive recovery in 
schizophrenia. Cognitive enhancing drugs have not been 
shown to be completely successful, and consequently, 
new therapeutic paradigms to improve cognition in 
schizophrenia need to be tested. The optimal approach 
may require a combination of  specific drug treatment 
with cognitive training intervention. Finally, examining 
the prognostic correlation of  baseline BDNF levels and 
the final outcome would be useful in establishing the 
status of  BDNF as a marker of  cognitive recovery in 
schizophrenia. For all these reasons, considering BDNF 
a biomarker of  cognitive recovery in schizophrenia may 
be promising but still premature.
ACKNOWLEDGMENTS
The authors would like also to thank the Miguel Servet 
Researcher’s stabilisation program of  “Instituto de Salud 
Carlos Ⅲ” from the Spanish government and “Direcció 
d’Estratègia i Coordinació del Departament de Salut” 
from the Generalitat de Catalunya where A.M.G belongs 
to. I.L-V. and A.M.G. belong also to the HERACLES 
RETIC, group RD06/0009/1003, supported by the In-
stituto de Salud Carlos Ⅲ.
REFERENCES
1 Oertel-Knöchel V, Bittner RA, Knöchel C, Prvulovic D, 
Hampel H. Discovery and development of integrative bio-
logical markers for schizophrenia. Prog Neurobiol 2011; 95: 
686-702 [PMID: 21664943 DOI: 10.1016/j.pneurobio]
2 Straub RE, Weinberger DR. Schizophrenia genes - famine 
to feast. Biol Psychiatry 2006; 60: 81-83 [PMID: 16843093 DOI: 
10.1016/j.biopsych.2006.06.002]
3 Schönknecht P, Hempel A, Hunt A, Seidl U, Volkmann M, 
Pantel J, Schröder J. Cerebrospinal fluid tau protein levels in 
schizophrenia. Eur Arch Psychiatry Clin Neurosci 2003; 253: 
100-102 [PMID: 12799749]
4 Koike S, Takano Y, Iwashiro N, Satomura Y, Suga M, 
Nagai T, Natsubori T, Tada M, Nishimura Y, Yamasaki S, 
Takizawa R, Yahata N, Araki T, Yamasue H, Kasai K. A 
multimodal approach to investigate biomarkers for psycho-
sis in a clinical setting: the integrative neuroimaging studies 
in schizophrenia targeting for early intervention and pre-
vention (IN-STEP) project. Schizophr Res 2013; 143: 116-124 
[PMID: 23219075 DOI: 10.1016/j.schres.2012.11.012]
5 Nurjono M, Lee J, Chong SA. A Review of Brain-derived 
Neurotrophic Factor as a Candidate Biomarker in Schizo-
phrenia. Clin Psychopharmacol Neurosci 2012; 10: 61-70 [PMID: 
23431036 DOI: 10.9758/cpn.2012.10.2.61]
6 Breier A. Developing drugs for cognitive impairment in 
schizophrenia. Schizophr Bull 2005; 31: 816-822 [PMID: 
16150959 DOI: 10.1093/schbul/sbi051]
7 Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, 
“just the facts” 5. Treatment and prevention. Past, present, 
and future. Schizophr Res 2010; 122: 1-23 [PMID: 20655178 
DOI: 10.1016/j.schres.2010.05.025]
8 Yamada K, Nabeshima T. Brain-derived neurotrophic fac-
tor/TrkB signaling in memory processes. J Pharmacol Sci 
2003; 91: 267-270 [PMID: 12719654 DOI: 10.1254/jphs.91.267]
9 Bekinschtein P, Cammarota M, Katche C, Slipczuk L, Ros-
sato JI, Goldin A, Izquierdo I, Medina JH. BDNF is essential 
to promote persistence of long-term memory storage. Proc 
Natl Acad Sci USA 2008; 105: 2711-2716 [PMID: 18263738 
DOI: 10.1073/pnas.0711863105]
10 Nakajo Y, Miyamoto S, Nakano Y, Xue JH, Hori T, Yanamoto 
H. Genetic increase in brain-derived neurotrophic factor 
levels enhances learning and memory. Brain Res 2008; 1241: 
103-109 [PMID: 18801341 DOI: 10.1016/j.brainres.2008.08.080]
11 Okada S, Yokoyama M, Toko H, Tateno K, Moriya J, Shi-
mizu I, Nojima A, Ito T, Yoshida Y, Kobayashi Y, Katagiri 
H, Minamino T, Komuro I. Brain-derived neurotrophic fac-
tor protects against cardiac dysfunction after myocardial 
infarction via a central nervous system-mediated pathway. 
Arterioscler Thromb Vasc Biol 2012; 32: 1902-1909 [PMID: 
22556331 DOI: 10.1161/ATVBAHA.112.248930]
12 Donovan MJ, Lin MI, Wiegn P, Ringstedt T, Kraemer R, 
Hahn R, Wang S, Ibañez CF, Rafii S, Hempstead BL. Brain 
derived neurotrophic factor is an endothelial cell survival 
factor required for intramyocardial vessel stabilization. De-
velopment 2000; 127: 4531-4540 [PMID: 11023857]
13 Renné C, Willenbrock K, Küppers R, Hansmann ML, Bräun-
inger A. Autocrine- and paracrine-activated receptor tyro-
sine kinases in classic Hodgkin lymphoma. Blood 2005; 105: 
4051-4059 [PMID: 15677564 DOI: 10.1182/blood-2004-10-4008]
14 Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. 
A neurotrophin axis in myeloma: TrkB and BDNF promote 
tumor-cell survival. Blood 2005; 105: 4429-4436 [PMID: 
15657181 DOI: 10.1182/blood-2004-08-3096]
15 Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van 
Garderen E, Peeper DS. Suppression of anoikis and induc-
tion of metastasis by the neurotrophic receptor TrkB. Nature 
2004; 430: 1034-1039 [PMID: 15329723 DOI: 10.1038/na-
ture02765]
16 Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, 
Camoratto AM, Evans AE, Brodeur GM. Resistance to che-
motherapy mediated by TrkB in neuroblastomas. Cancer Res 
2002; 62: 6462-6466 [PMID: 12438236]
17 Yang ZF, Ho DW, Lam CT, Luk JM, Lum CT, Yu WC, Poon 
RT, Fan ST. Identification of brain-derived neurotrophic 
factor as a novel functional protein in hepatocellular carci-
noma. Cancer Res 2005; 65: 219-225 [PMID: 15665298]
18 Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, 
Masiakowski P, Thoenen H, Barde YA. Molecular cloning 
and expression of brain-derived neurotrophic factor. Nature 
1989; 341: 149-152 [PMID: 2779653 DOI: 10.1038/341149a0]
19 Acheson A, Barker PA, Alderson RF, Miller FD, Murphy 
RA. Detection of brain-derived neurotrophic factor-like 
activity in fibroblasts and Schwann cells: inhibition by an-
tibodies to NGF. Neuron 1991; 7: 265-275 [PMID: 1873030 
DOI: 10.1016/0896-6273(91)90265-2]
20 Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of 
cell survival by secreted proneurotrophins. Science 2001; 294: 
1945-1948 [PMID: 11729324 DOI: 10.1126/science.1065057]
21 Serra-Millàs M, López-Vílchez I, Navarro V, Galán AM, 
Escolar G, Penadés R, Catalán R, Fañanás L, Arias B, Gastó 
C. Changes in plasma and platelet BDNF levels induced 
by S-citalopram in major depression. Psychopharmacol-
ogy (Berl) 2011; 216: 1-8 [PMID: 21308467 DOI: 10.1007/
s00213-011-2180-0]
22 Fujimura H, Altar CA, Chen R, Nakamura T, Nakahashi 
T, Kambayashi J, Sun B, Tandon NN. Brain-derived neuro-
trophic factor is stored in human platelets and released by 
agonist stimulation. Thromb Haemost 2002; 87: 728-734 [PMID: 
12008958]
23 Pliego-Rivero FB, Bayatti N, Giannakoulopoulos X, Glover V, 
Bradford HF, Stern G, Sandler M. Brain-derived neurotrophic 
factor in human platelets. Biochem Pharmacol 1997; 54: 207-209 
[PMID: 9296368 DOI: 10.1016/S0006-2952(97)00073-7]
24 Yamamoto H, Gurney ME. Human platelets contain brain-
derived neurotrophic factor. J Neurosci 1990; 10: 3469-3478 
[PMID: 2230938]
99 December 22, 2013|Volume 3|Issue 4|WJP|www.wjgnet.com
Penadés R et al . BDNF in schizophrenia
25 Kerschensteiner M, Gallmeier E, Behrens L, Leal VV, Mis-
geld T, Klinkert WE, Kolbeck R, Hoppe E, Oropeza-Wekerle 
RL, Bartke I, Stadelmann C, Lassmann H, Wekerle H, Hohl-
feld R. Activated human T cells, B cells, and monocytes 
produce brain-derived neurotrophic factor in vitro and in 
inflammatory brain lesions: a neuroprotective role of in-
flammation? J Exp Med 1999; 189: 865-870 [PMID: 10049950 
DOI: 10.1084/jem.189.5.865]
26 Hiltunen JO, Arumäe U, Moshnyakov M, Saarma M. Ex-
pression of mRNAs for neurotrophins and their receptors 
in developing rat heart. Circ Res 1996; 79: 930-939 [PMID: 
8888685 DOI: 10.1161/01.RES.79.5.930]
27 Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, 
Lindsay RM, Yancopoulos GD. Neurotrophin-3: a neuro-
trophic factor related to NGF and BDNF. Science 1990; 247: 
1446-1451 [PMID: 2321006 DOI: 10.1126/science.2321006]
28 Maisonpierre PC, Le Beau MM, Espinosa R, Ip NY, Bellus-
cio L, de la Monte SM, Squinto S, Furth ME, Yancopoulos 
GD. Human and rat brain-derived neurotrophic factor and 
neurotrophin-3: gene structures, distributions, and chro-
mosomal localizations. Genomics 1991; 10: 558-568 [PMID: 
1889806 DOI: 10.1016/0888-7543(91)90436-I]
29 Nakahashi T, Fujimura H, Altar CA, Li J, Kambayashi 
J, Tandon NN, Sun B. Vascular endothelial cells synthe-
size and secrete brain-derived neurotrophic factor. FEBS 
Lett 2000; 470: 113-117 [PMID: 10734218 DOI: 10.1016/
S0014-5793(00)01302-8]
30 Karege F, Schwald M, Cisse M. Postnatal developmental 
profile of brain-derived neurotrophic factor in rat brain and 
platelets. Neurosci Lett 2002; 328: 261-264 [PMID: 12147321 
DOI: 10.1016/S0304-3940(02)00529-3]
31 Lommatzsch M, Braun A, Mannsfeldt A, Botchkarev VA, 
Botchkareva NV, Paus R, Fischer A, Lewin GR, Renz H. 
Abundant production of brain-derived neurotrophic fac-
tor by adult visceral epithelia. Implications for paracrine 
and target-derived Neurotrophic functions. Am J Pathol 
1999; 155: 1183-1193 [PMID: 10514401 DOI: 10.1016/
S0002-9440(10)65221-2]
32 Pan W, Banks WA, Fasold MB, Bluth J, Kastin AJ. Trans-
port of brain-derived neurotrophic factor across the blood-
brain barrier. Neuropharmacology 1998; 37: 1553-1561 [PMID: 
9886678 DOI: 10.1016/S0028-3908(98)00141-5]
33 Brunoni AR, Lopes M, Fregni F. A systematic review and 
meta-analysis of clinical studies on major depression and 
BDNF levels: implications for the role of neuroplasticity in 
depression. Int J Neuropsychopharmacol 2008; 11: 1169-1180 
[PMID: 18752720 DOI: 10.1017/S1461145708009309]
34 Karege F, Bondolfi G, Gervasoni N, Schwald M, Aubry JM, 
Bertschy G. Low brain-derived neurotrophic factor (BDNF) 
levels in serum of depressed patients probably results from 
lowered platelet BDNF release unrelated to platelet reactiv-
ity. Biol Psychiatry 2005; 57: 1068-1072 [PMID: 15860348 DOI: 
10.1016/j.biopsych.2005.01.008]
35 Trajkovska V, Marcussen AB, Vinberg M, Hartvig P, Aznar 
S, Knudsen GM. Measurements of brain-derived neuro-
trophic factor: methodological aspects and demographical 
data. Brain Res Bull 2007; 73: 143-149 [PMID: 17499648 DOI: 
10.1016/j.brainresbull.2007.03.009]
36 Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, 
Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada 
S, Iyo M. Alterations of serum levels of brain-derived neu-
rotrophic factor (BDNF) in depressed patients with or with-
out antidepressants. Biol Psychiatry 2003; 54: 70-75 [PMID: 
12842310 DOI: 10.1016/S0006-3223(03)00181-1]
37 Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi 
M, Someya T, Nawa H. Decreased levels of brain-derived 
neurotrophic factor in serum of chronic schizophrenic pa-
tients. Psychiatry Res 2002; 110: 249-257 [PMID: 12127475 
DOI: 10.1016/S0165-1781(02)00127-0]
38 Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, 
Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Bu-
chkremer G, Schott K. BDNF serum and CSF concentrations 
in Alzheimer’s disease, normal pressure hydrocephalus and 
healthy controls. J Psychiatr Res 2007; 41: 387-394 [PMID: 
16554070 DOI: 10.1016/j.jpsychires.2006.01.014]
39 Azoulay D, Vachapova V, Shihman B, Miler A, Karni A. 
Lower brain-derived neurotrophic factor in serum of relaps-
ing remitting MS: reversal by glatiramer acetate. J Neuroim-
munol 2005; 167: 215-218 [PMID: 16083971 DOI: 10.1016/
j.jneuroim.2005.07.001]
40 Nakazato M, Hashimoto K, Shimizu E, Kumakiri C, Koi-
zumi H, Okamura N, Mitsumori M, Komatsu N, Iyo M. 
Decreased levels of serum brain-derived neurotrophic 
factor in female patients with eating disorders. Biol Psy-
chiatry 2003; 54: 485-490 [PMID: 12915293 DOI: 10.1016/
S0006-3223(02)01746-8]
41 Hong CJ, Liou YJ, Tsai SJ. Effects of BDNF polymorphisms 
on brain function and behavior in health and disease. Brain 
Res Bull 2011; 86: 287-297 [PMID: 21924328 DOI: 10.1016/
j.brainresbull.2011.08.019]
42 Gratacòs M, González JR, Mercader JM, de Cid R, Urre-
tavizcaya M, Estivill X. Brain-derived neurotrophic factor 
Val66Met and psychiatric disorders: meta-analysis of case-
control studies confirm association to substance-related 
disorders, eating disorders, and schizophrenia. Biol Psy-
chiatry 2007; 61: 911-922 [PMID: 17217930 DOI: 10.1016/
j.biopsych.2006.08.025]
43 Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hemp-
stead BL, Lee FS. Variant brain-derived neurotrophic factor 
(BDNF) (Met66) alters the intracellular trafficking and activ-
ity-dependent secretion of wild-type BDNF in neurosecre-
tory cells and cortical neurons. J Neurosci 2004; 24: 4401-4411 
[PMID: 15128854 DOI: 10.1523/JNEUROSCI.0348-04.2004]
44 Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana 
BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean M, 
Lu B, Weinberger DR. The BDNF val66met polymorphism 
affects activity-dependent secretion of BDNF and human 
memory and hippocampal function. Cell 2003; 112: 257-269 
[PMID: 12553913 DOI: 10.1016/S0092-8674(03)00035-7]
45 Kawashima K, Ikeda M, Kishi T, Kitajima T, Yamanouchi 
Y, Kinoshita Y, Okochi T, Aleksic B, Tomita M, Okada T, 
Kunugi H, Inada T, Ozaki N, Iwata N. BDNF is not associ-
ated with schizophrenia: data from a Japanese population 
study and meta-analysis. Schizophr Res 2009; 112: 72-79 
[PMID: 19406621 DOI: 10.1016/j.schres.2009.03.040]
46 Weinberger DR, Marenco S. Schizophrenia as a neurode-
velopmental disorder: A review of the concept. In: Hirsch 
SR, Weinberger DR (ed). Schizophrenia. London: Blackwell, 
1995: 326
47 Murray RM, Lewis SW. Is schizophrenia a neurodevelop-
mental disorder? Br Med J (Clin Res Ed) 1987; 295: 681-682 
[PMID: 3117295 DOI: 10.1136/bmj.295.6600.681]
48 Tanaka S, Sekino Y, Shirao T. The effects of neurotrophin-3 
and brain-derived neurotrophic factor on cerebellar granule 
cell movement and neurite extension in vitro. Neuroscience 
2000; 97: 727-734 [PMID: 10842017 DOI: 10.1016/S0306-
4522(00)00049-X]
49 Pillai A. Brain-derived neurotropic factor/TrkB signaling 
in the pathogenesis and novel pharmacotherapy of schizo-
phrenia. Neurosignals 2008; 16: 183-193 [PMID: 18253057 
DOI: 10.1159/000111562]
50 Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara 
DR. Reduced serum BDNF levels in schizophrenic patients 
on clozapine or typical antipsychotics. J Psychiatr Res 2007; 41: 
31-35 [PMID: 16546213 DOI: 10.1016/j.jpsychires.2006.01.005]
51 Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, 
Chen da C, Kosten TR, Zhang XY. Decreased serum BDNF 
levels in chronic institutionalized schizophrenia on long-
term treatment with typical and atypical antipsychotics. 
Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 1508-1512 
100 December 22, 2013|Volume 3|Issue 4|WJP|www.wjgnet.com
Penadés R et al . BDNF in schizophrenia
[PMID: 19720106 DOI: 10.1016/j.pnpbp.2009.08.011]
52 Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased 
BDNF in serum of patients with chronic schizophrenia on 
long-term treatment with antipsychotics. Neurosci Lett 2005; 
382: 27-32 [PMID: 15911116 DOI: 10.1016/j.neulet.2005.02.054]
53 Zhang XY, Tan YL, Zhou DF, Cao LY, Wu GY, Xu Q, Shen Y, 
Haile CN, Kosten TA, Kosten TR. Serum BDNF levels and 
weight gain in schizophrenic patients on long-term treat-
ment with antipsychotics. J Psychiatr Res 2007; 41: 997-1004 
[PMID: 17095017 DOI: 10.1016/j.jpsychires.2006.08.007]
54 Ikeda Y, Yahata N, Ito I, Nagano M, Toyota T, Yoshikawa 
T, Okubo Y, Suzuki H. Low serum levels of brain-derived 
neurotrophic factor and epidermal growth factor in patients 
with chronic schizophrenia. Schizophr Res 2008; 101: 58-66 
[PMID: 18289832 DOI: 10.1016/j.schres.2008.01.017]
55 Huang TL, Lee CT. Associations between serum brain-
derived neurotrophic factor levels and clinical phenotypes 
in schizophrenia patients. J Psychiatr Res 2006; 40: 664-668 
[PMID: 16386272 DOI: 10.1016/j.jpsychires.2005.11.004]
56 Shimizu E, Hashimoto K, Watanabe H, Komatsu N, Oka-
mura N, Koike K, Shinoda N, Nakazato M, Kumakiri C, 
Okada S, Iyo M. Serum brain-derived neurotrophic factor 
(BDNF) levels in schizophrenia are indistinguishable from 
controls. Neurosci Lett 2003; 351: 111-114 [PMID: 14583394 
DOI: 10.1016/j.neulet.2003.08.004]
57 Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-
Abreu PS, Kapczinski F. Serum levels of brain-derived neu-
rotrophic factor in patients with schizophrenia and bipolar 
disorder. Neurosci Lett 2007; 420: 45-48 [PMID: 17442489 
DOI: 10.1016/j.neulet.2007.04.001]
58 Reis HJ, Nicolato R, Barbosa IG, Teixeira do Prado PH, 
Romano-Silva MA, Teixeira AL. Increased serum levels of 
brain-derived neurotrophic factor in chronic institutional-
ized patients with schizophrenia. Neurosci Lett 2008; 439: 
157-159 [PMID: 18514407 DOI: 10.1016/j.neulet.2008.05.022]
59 Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. 
Brain-derived neurotrophic factor levels in schizophrenia: a 
systematic review with meta-analysis. Mol Psychiatry 2011; 
16: 960-972 [PMID: 20733577 DOI: 10.1038/mp.2010.88]
60 Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. 
Brain derived neurotropic factor in first-episode psychosis. 
Schizophr Res 2007; 91: 1-5 [PMID: 17306505 DOI: 10.1016/
j.schres.2006.12.026]
61 Jindal RD, Pillai AK, Mahadik SP, Eklund K, Montrose 
DM, Keshavan MS. Decreased BDNF in patients with an-
tipsychotic naïve first episode schizophrenia. Schizophr 
Res 2010; 119 : 47-51 [PMID: 20096541 DOI: 10.1016/
j.schres.2009.12.035]
62 Pillai A, Kale A, Joshi S, Naphade N, Raju MS, Nasrallah 
H, Mahadik SP. Decreased BDNF levels in CSF of drug-
naive first-episode psychotic subjects: correlation with 
plasma BDNF and psychopathology. Int J Neuropsycho-
pharmacol 2010; 13: 535-539 [PMID: 19941699 DOI: 10.1017/
S1461145709991015]
63 Rizos EN, Papathanasiou M, Michalopoulou PG, Mazioti 
A, Douzenis A, Kastania A, Nikolaidou P, Laskos E, Vasi-
lopoulou K, Lykouras L. Association of serum BDNF lev-
els with hippocampal volumes in first psychotic episode 
drug-naive schizophrenic patients. Schizophr Res 2011; 129: 
201-204 [PMID: 21470828 DOI: 10.1016/j.schres.2011.03.011]
64 Favalli G, Li J, Belmonte-de-Abreu P, Wong AH, Daskalakis 
ZJ. The role of BDNF in the pathophysiology and treat-
ment of schizophrenia. J Psychiatr Res 2012; 46: 1-11 [PMID: 
22030467 DOI: 10.1016/j.jpsychires.2011.09.022]
65 Buckley PF, Pillai A, Howell KR. Brain-derived neuro-
trophic factor: findings in schizophrenia. Curr Opin Psy-
chiatry 2011; 24: 122-127 [PMID: 21248641 DOI: 10.1097/
YCO.0b013e3283436eb7]
66 Guillin O, Demily C, Thibaut F. Brain-derived neurotrophic 
factor in schizophrenia and its relation with dopamine. 
Int Rev Neurobiol 2007; 78: 377-395 [PMID: 17349867 DOI: 
10.1016/S0074-7742(06)78012-6]
67 Guillin O, Griffon N, Diaz J, Le Foll B, Bezard E, Gross C, 
Lammers C, Stark H, Carroll P, Schwartz JC, Sokoloff P. Brain-
derived neurotrophic factor and the plasticity of the meso-
limbic dopamine pathway. Int Rev Neurobiol 2004; 59: 425-444 
[PMID: 15006497 DOI: 10.1016/S0074-7742(04)59016-5]
68 Sokoloff P, Guillin O, Diaz J, Carroll P, Griffon N. Brain-
derived neurotrophic factor controls dopamine D3 receptor 
expression: implications for neurodevelopmental psychiatric 
disorders. Neurotox Res 2002; 4: 671-678 [PMID: 12709305 
DOI: 10.1080/1029842021000045499]
69 Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis 
DA. Decreased glutamic acid decarboxylase67 messenger 
RNA expression in a subset of prefrontal cortical gamma-
aminobutyric acid neurons in subjects with schizophrenia. 
Arch Gen Psychiatry 2000; 57: 237-245 [PMID: 10711910 DOI: 
10.1001/archpsyc.57.3.237]
70 Djalali S, Höltje M, Grosse G, Rothe T, Stroh T, Grosse J, 
Deng DR, Hellweg R, Grantyn R, Hörtnagl H, Ahnert-Hilg-
er G. Effects of brain-derived neurotrophic factor (BDNF) on 
glial cells and serotonergic neurones during development. J 
Neurochem 2005; 92: 616-627 [PMID: 15659231 DOI: 10.1111/
j.1471-4159.2004.02911.x]
71 Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, 
Repérant C, Guilloux JP, Coudoré F, Hen R, Gardier AM. 
Behavioral and serotonergic consequences of decreasing or 
increasing hippocampus brain-derived neurotrophic factor 
protein levels in mice. Neuropharmacology 2008; 55: 1006-1014 
[PMID: 18761360 DOI: 10.1016/j.neuropharm.2008.08.001]
72 Lang UE, Hellweg R, Gallinat J. Association of BDNF serum 
concentrations with central serotonergic activity: evidence 
from auditory signal processing. Neuropsychopharmacol-
ogy 2005; 30: 1148-1153 [PMID: 15668721 DOI: 10.1038/
sj.npp.1300666]
73 Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA. 
Brain volume in first-episode schizophrenia: systematic 
review and meta-analysis of magnetic resonance imaging 
studies. Br J Psychiatry 2006; 188: 510-518 [PMID: 16738340 
DOI: 10.1192/bjp.188.6.510]
74 Wong AH, Van Tol HH. Schizophrenia: from phenomenol-
ogy to neurobiology. Neurosci Biobehav Rev 2003; 27: 269-306 
[PMID: 12788337 DOI: 10.1016/S0149-7634(03)00035-6]
75 Cahn W, Hulshoff Pol HE, Lems EB, van Haren NE, Schnack 
HG, van der Linden JA, Schothorst PF, van Engeland H, Kahn 
RS. Brain volume changes in first-episode schizophrenia: a 
1-year follow-up study. Arch Gen Psychiatry 2002; 59: 1002-1010 
[PMID: 12418933 DOI: 10.1001/archpsyc.59.11.1002]
76 Aid T, Kazantseva A, Piirsoo M, Palm K, Timmusk T. Mouse 
and rat BDNF gene structure and expression revisited. J 
Neurosci Res 2007; 85: 525-535 [PMID: 17149751 DOI: 10.1002/
jnr.21139]
77 Shimada A, Mason CA, Morrison ME. TrkB signaling mod-
ulates spine density and morphology independent of den-
drite structure in cultured neonatal Purkinje cells. J Neurosci 
1998; 18: 8559-8570 [PMID: 9786964]
78 Yacoubian TA, Lo DC. Truncated and full-length TrkB recep-
tors regulate distinct modes of dendritic growth. Nat Neurosci 
2000; 3: 342-349 [PMID: 10725923 DOI: 10.1038/73911]
79 Minichiello L, Korte M, Wolfer D, Kühn R, Unsicker K, 
Cestari V, Rossi-Arnaud C, Lipp HP, Bonhoeffer T, Klein R. 
Essential role for TrkB receptors in hippocampus-mediated 
learning. Neuron 1999; 24: 401-414 [PMID: 10571233 DOI: 
10.1016/S0896-6273(00)80853-3]
80 Gärtner A, Polnau DG, Staiger V, Sciarretta C, Minichiello 
L, Thoenen H, Bonhoeffer T, Korte M. Hippocampal long-
term potentiation is supported by presynaptic and postsyn-
aptic tyrosine receptor kinase B-mediated phospholipase 
Cgamma signaling. J Neurosci 2006; 26: 3496-3504 [PMID: 
16571757 DOI: 10.1523/JNEUROSCI.3792-05.2006]
101 December 22, 2013|Volume 3|Issue 4|WJP|www.wjgnet.com
Penadés R et al . BDNF in schizophrenia
81 Zhang XY, Liang J, Chen da C, Xiu MH, Yang FD, Kosten 
TA, Kosten TR. Low BDNF is associated with cognitive 
impairment in chronic patients with schizophrenia. Psycho-
pharmacology (Berl) 2012; 222: 277-284 [PMID: 22274000 DOI: 
10.1007/s00213-012-2643-y]
82 Niitsu T, Shirayama Y, Matsuzawa D, Hasegawa T, Kanahara 
N, Hashimoto T, Shiraishi T, Shiina A, Fukami G, Fujisaki M, 
Watanabe H, Nakazato M, Asano M, Kimura S, Hashimoto K, 
Iyo M. Associations of serum brain-derived neurotrophic factor 
with cognitive impairments and negative symptoms in schizo-
phrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 
1836-1840 [PMID: 21930178 DOI: 10.1016/j.pnpbp.2011.09.004]
83 Tyler WJ, Alonso M, Bramham CR, Pozzo-Miller LD. From 
acquisition to consolidation: on the role of brain-derived neu-
rotrophic factor signaling in hippocampal-dependent learning. 
Learn Mem 2002; 9: 224-237 [PMID: 12359832 DOI: 10.1101/
lm.51202]
84 Cirulli F, Berry A, Chiarotti F, Alleva E. Intrahippocampal 
administration of BDNF in adult rats affects short-term 
behavioral plasticity in the Morris water maze and perfor-
mance in the elevated plus-maze. Hippocampus 2004; 14: 
802-807 [PMID: 15382250 DOI: 10.1002/hipo.10220]
85 Kang H, Welcher AA, Shelton D, Schuman EM. Neuro-
trophins and time: different roles for TrkB signaling in hip-
pocampal long-term potentiation. Neuron 1997; 19: 653-664 
[PMID: 9331355 DOI: 10.1016/S0896-6273(00)80378-5]
86 Lu B, Chang JH. Regulation of neurogenesis by neurotroph-
ins: implications in hippocampus-dependent memory. Neu-
ron Glia Biol 2004; 1: 377-384 [PMID: 18634594 DOI: 10.1017/
S1740925X05000232]
87 Chen da C, Wang J, Wang B, Yang SC, Zhang CX, Zheng 
YL, Li YL, Wang N, Yang KB, Xiu MH, Kosten TR, Zhang 
XY. Decreased levels of serum brain-derived neurotrophic 
factor in drug-naïve first-episode schizophrenia: relationship 
to clinical phenotypes. Psychopharmacology (Berl) 2009; 207: 
375-380 [PMID: 19787338 DOI: 10.1007/s00213-009-1665-6]
88 Smith GN, Thornton AE, Lang DJ, Macewan GW, Ehmann 
TS, Kopala LC, Tee K, Shiau G, Voineskos AN, Kennedy JL, 
Honer WG. Hippocampal volume and the brain-derived 
neurotrophic factor Val66Met polymorphism in first episode 
psychosis. Schizophr Res 2012; 134: 253-259 [PMID: 22192502 
DOI: 10.1016/j.schres.2011.11.022]
89 Eisenberg DP, Ianni AM, Wei SM, Kohn PD, Kolachana B, 
Apud J, Weinberger DR, Berman KF. Brain-derived neu-
rotrophic factor (BDNF) Val(66)Met polymorphism differ-
entially predicts hippocampal function in medication-free 
patients with schizophrenia. Mol Psychiatry 2013; 18: 713-720 
[PMID: 23319002 DOI: 10.1038/mp.2012.187]
90 Gama CS, Berk M, Andreazza AC, Kapczinski F, Belmonte-
de-Abreu P. Serum levels of brain-derived neurotrophic fac-
tor and thiobarbituric acid reactive substances in chronically 
medicated schizophrenic patients: a positive correlation. 
Rev Bras Psiquiatr 2008; 30: 337-340 [PMID: 19142408 DOI: 
10.1590/S1516-44462008000400006]
91 Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz 
O, Mellon SH. Is serum brain-derived neurotrophic factor a 
biomarker for cognitive enhancement in schizophrenia? Biol 
Psychiatry 2009; 66: 549-553 [PMID: 19368899 DOI: 10.1016/
j.biopsych.2009.02.017]
92 Xu M, Li S, Xing Q, Gao R, Feng G, Lin Z, St Clair D, He L. 
Genetic variants in the BDNF gene and therapeutic response 
to risperidone in schizophrenia patients: a pharmacogenetic 
study. Eur J Hum Genet 2010; 18: 707-712 [PMID: 20087404 DOI: 
10.1038/ejhg.2009.238]
93 Zai GC, Zai CC, Chowdhury NI, Tiwari AK, Souza RP, Lieber-
man JA, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL. The 
role of brain-derived neurotrophic factor (BDNF) gene variants 
in antipsychotic response and antipsychotic-induced weight 
gain. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 96-101 
[PMID: 22642961 DOI: 10.1016/j.pnpbp.2012.05.014]
94 Zhang JP, Lencz T, Geisler S, DeRosse P, Bromet EJ, Mal-
hotra AK. Genetic variation in BDNF is associated with an-
tipsychotic treatment resistance in patients with schizophre-
nia. Schizophr Res 2013; 146: 285-288 [PMID: 23433505 DOI: 
10.1016/j.schres.2013.01.020]
95 Tsai A, Liou YJ, Hong CJ, Wu CL, Tsai SJ, Bai YM. As-
sociation study of brain-derived neurotrophic factor gene 
polymorphisms and body weight change in schizophrenic 
patients under long-term atypical antipsychotic treatment. 
Neuromolecular Med 2011; 13: 328-333 [PMID: 21956459 DOI: 
10.1007/s12017-011-8159-5]
96 Zhang XY, Zhang WF, Zhou DF, Chen da C, Xiu MH, Wu 
HR, Haile CN, Kosten TA, Kosten TR. Brain-derived neuro-
trophic factor levels and its Val66Met gene polymorphism 
predict tardive dyskinesia treatment response to Ginkgo bi-
loba. Biol Psychiatry 2012; 72: 700-706 [PMID: 22695185 DOI: 
10.1016/j.biopsych.2012.04.032]
97 Xu MQ, St Clair D, Feng GY, Lin ZG, He G, Li X, He L. BDNF 
gene is a genetic risk factor for schizophrenia and is related to 
the chlorpromazine-induced extrapyramidal syndrome in the 
Chinese population. Pharmacogenet Genomics 2008; 18: 449-457 
[PMID: 18408624 DOI: 10.1097/FPC.0b013e3282f85e26]
P- Reviewers: Guardia-Olmos J, Numakawa T 
S- Editor: Song XX    L- Editor: A    E- Editor: Liu XM
102 December 22, 2013|Volume 3|Issue 4|WJP|www.wjgnet.com
Penadés R et al . BDNF in schizophrenia
